
Book Review: Veteran journalist explores impact of private equity industry on US society
Stunned by what she witnessed, the veteran journalist was determined to get to the bottom of a little understood, lightly regulated industry that owns hospitals, day care centers, supermarket chains, newspapers, commercial and residential real estate, and much more. The big names are
Blackstone,
the Carlyle Group, Apollo Global Management, KKR and
Cerberus Capital Management.
But what, she wondered, do they actually do?
The result of her inquiry is 'Bad Company: Private Equity and the Death of the American Dream,' a deeply reported, briskly paced and highly disturbing account of how the private equity industry has 'reshaped the American economy to serve its own interests, creating a new class of billionaires while stripping ordinary people of their livelihoods, their health care, their homes, and their sense of security.'
Instead of focusing on the macroeconomic level, she tells the story through four remarkable people whose lives were upended after private equity acquisitions. Liz was a
Toys R Us
floor supervisor when the storied retailer was acquired by Mitt Romney's company, Bain Capital, and other investors and eventually went under, laying off 33,000 employees without severance pay.
Roger practiced medicine in rural Wyoming when private equity acquired his hospital and gutted services. Natalia was working for local Gannett newspapers at a time when the chain eliminated more than half its staff after years of private equity ownership. And Loren, an affordable housing organizer, escaped public housing only to end up in a mold- and rodent-infested apartment complex in northern Virginia owned by a private equity firm on the other side of the continent.
Greenwell has written an essential guide to an industry that operates largely in the shadows, donates generously to Democrats and Republicans in Congress to keep it that way, and has contributed substantially to the hollowing out of the American dream. Despite her immersion in this predatory world, she remains surprisingly optimistic. 'Every year,' she writes, 'a few more people like Liz, Roger, Natalia and Loren start fighting back.'
___
AP book reviews:
https://apnews.com/hub/book-reviews
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
China's SpaceX rival LandSpace eyes IPO in Shanghai
BEIJING (Reuters) -Chinese rocket developer LandSpace Technology is seeking to list on the Shanghai Stock Exchange's tech-focussed STAR Market, according to a document released by the securities regulator on Tuesday. The document did not state how much the company aims to raise. Beijing-based LandSpace was the world's first company to launch a methane-liquid oxygen rocket in July 2023, ahead of U.S. rivals including Elon Musk's SpaceX and Jeff Bezos's Blue Origin. It completed a test of the first-stage propulsion system of its Zhuque-3 launch vehicle in June, paving the way for the reusable rocket's first launch scheduled for the second half of 2025, according to a statement posted on the company's WeChat account. A successful test of Zhuque-3 would make LandSpace the second company after SpaceX to launch a reusable rocket, which is cheaper and faster in launch turnaround compared with expendable rockets. Founded in 2015, LandSpace has secured funding from investors including venture capital firm HongShan, known at that time as Sequoia Capital China, the investment arm of Chinese property developer Country Garden and the state-backed China SME Development Fund. LandSpace raised 900 million yuan ($125 million) in December from a state-owned fund focussed on advanced manufacturing, while in 2020 it raised 1.2 billion yuan, Chinese corporate databases showed. ($1 = 7.1796 Chinese yuan renminbi) Connectez-vous pour accéder à votre portefeuille
Yahoo
18 minutes ago
- Yahoo
Murphy opts not to take up Charlton CEO role
Dane Murphy will no longer be taking over as CEO at Charlton Athletic, the club has announced. The American former professional footballer has previously held the same role at Barnsley and Nottingham Forest, overseeing the Reds' promotion to the Premier League in 2021-22. The Addicks announced Murphy would take the helm at The Valley last month. But the club says the two parties have now agreed the former DC United and New York Cosmos player will not step into the role. "This decision was made in light of personal and professional considerations on Dane's part, and we fully respect and support his choice," chairman Gavin Carter told the club's website. "While Dane had not formally commenced the position, we are grateful for the time and effort he dedicated during the exploratory and planning phases. We thank him for his integrity throughout this process and wish him the very best in his future endeavours." Charlton begin their first season back in the Championship following promotion against Watford on Saturday, 9 August. Charlton set to appoint Murphy as CEO Latest Charlton Athletic news, analysis and fan views Listen to Charlton Athletic content on BBC Sounds
Yahoo
18 minutes ago
- Yahoo
Aldevron Launches New Innovation Center in Waltham, MA
Strategic expansion places Aldevron at the heart of the Boston biotech corridor, fueling next-generation breakthroughs in genomic medicine FARGO, N.D. & WALTHAM, Mass., July 30, 2025--(BUSINESS WIRE)--Aldevron, a Danaher company, and a global leader in the production of DNA, RNA and protein in the genomic medicine space, today announced the planned opening of its new Innovation Center in Waltham, Massachusetts. The milestone marks a bold step in Aldevron's mission to accelerate innovation in genomic medicines while deepening its presence in one of the world's most dynamic biotech hubs. The new Waltham site is designed to fast-track advancements in the manufacture of DNA, RNA and proteins for advanced therapies, expanding Aldevron's capabilities in cell-free DNA, molecular biology, gene editing, and mRNA analytics. By establishing a base in the Boston area, Aldevron is positioning itself at the epicenter of biotech innovation—enabling closer collaboration with clients, faster project timelines and enhanced support for the development of advanced therapies. "Establishing a presence in Waltham puts Aldevron at the crossroads of scientific discovery," said Venkata Indurthi, Chief Scientific Officer at Aldevron. "This Innovation Center is a launchpad for transformative research, empowering us to innovate, collaborate and grow alongside the brightest minds in biotech." The Waltham Innovation Center will complement Aldevron's established scientific teams in Fargo, ND, and Madison, WI, and will serve as a catalyst for recruiting top talent from Boston's vibrant biotech community. "Our recent role in the groundbreaking 'Baby KJ' CRISPR therapy delivery demonstrates the life-changing impact that comes from investing in innovation," said Jennifer Meade, President of Aldevron. "As one of the most established biotech partners in the U.S., this expansion is a natural evolution—opening new opportunities for growth, deeper client partnerships and greater support for the scientists shaping the future of medicine." About Aldevron Founded in 1998, Aldevron is a global leader in enabling the development of next-generation genomic medicines. As part of Danaher Corporation, Aldevron empowers scientists and innovators worldwide to advance transformative therapies that are redefining the future of medicine. Aldevron's expertise and integrated solutions have supported landmark achievements—including playing a key role in manufacturing the world's first mRNA-based personalized CRISPR therapy. With facilities in Fargo, ND, Madison, WI and Waltham, MA, Aldevron is at the forefront of accelerating scientific discovery and expanding the possibilities of gene editing, gene therapy and other breakthrough modalities. By partnering with leading researchers and organizations, Aldevron is helping to turn the promise of genomic medicine into reality for patients around the globe. To learn more about how Aldevron is advancing biological science, visit and follow the company on LinkedIn, Facebook and YouTube. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at View source version on Contacts Media Contact: Ellen ShaferSenior Director of (701) 219-0333